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Abstract
© 2016, Springer Science+Business Media New York.This paper presents a clinical  case of
successful  ulnar  pseudarthrosis  treatment using a gene-activated bone allograft  containing
VEGF (vascular endothelial growth factor) and BMP2 (bone morphogenetic protein 2) in the form
of a multicystron plasmid. Demineralized bone matrix with applied recombinant plasmid DNA
was grafted into the bone defect using the classical open surgical approach. Two months after
the surgery, the patient noticed the disappearance of pain including pain during activity. On X-
rays of ulna, signs of union in the form of callus formation were found.
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